Today, in Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. 2012), the Federal Circuit held that non-naturally occurring DNA is patent eligible as well as the use of a transformed, non-naturally occurring cell for screening drug candidates. Myriad’s method claims directed to “comparing” or “analyzing” DNA sequences were held to be patent-ineligible. A copy of the Federal Circuit’s decision is attached Federal Circuit Myriad Decision. A detailed analysis by Foley & Lardner, LLP and this blog post will follow.
Related Insights
June 26, 2025
Energy Current
EPA Signals Approval of Texas’ Class VI Injection Well Primacy: Streamlining Carbon Capture and Climate Action
In a significant move for environmental policy and energy innovation, the U.S. Environmental Protection Agency (EPA) has proposed to…
June 26, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
June 26, 2025
Foley Career Perspectives
Foley Pride Month Program: Generational Experiences of LGBTQIA+ Attorneys
Continuing our celebration of Pride Month, Foley & Lardner presented an engaging discussion with four of our LGBTQ+ attorneys.